

RECEIVED


MAY 06 2002

PTO/SB/08A (10-01) 6 2003

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
is not to be construed as a collection of information, unless it contains a
statistical record.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/762,587
		Filing Date	02/9/01
		First Named Inventor	Grillo-Lopez
		Art Unit	1616
		Examiner Name	tba
		Attorney Docket Number	37003-277847 (1998-30-0523VUS)
Sheet	1	of	1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials'	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Country Code ³ -Number ⁴ . Kind Code ⁵ (if known)				

Examiner
Signature

M. T. Davis

Date
Considered

06/17/05

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	09/762,587
Filing Date	02/9/01
First Named Inventor	Grillo-Lopez
Group Art Unit	1616
Examiner Name	tba
Attorney Docket Number	37003-277847 (1998-30-0523VUS)

MAY
06

TECH CENTER

2003

16
JULY 29 2003

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
TB		<p>Alas et al., "Rituximab Modifies the Cisplatin-Mitochondrial..." Clin Cancer Res., 2001, 7(3):709-23 (Abstract only)</p> <p>Alas et al. "Inhibition of Interleukin 10 by Rituximab Results..." Clin. Cancer Res. 2002, 8(3):836-45 (Abstract only)</p> <p>Cohen et al., "Large B-Cell Lymphoma Manifesting as an Invasive..." Leuk. Lymphoma (2002) 43(7):1485-7 (Abstract only)</p> <p>Di Gaelano et al., "Synergism between Fludarabine and Rituximab..." Br. J. Haematol., 2001, 114(4):800-9 (Abstract only)</p> <p>Juveid et al., "Treatment of Non-Hodgkin's Lymphoma with Radiolabeled Murine..." Cancer Research Dec. 1, 1995, Vol. 55 (pp. 5899-5907</p> <p>Muzaffar et al., Immunophenotypic analysis of Non-Hodgkin's Lymphoma, J. Pak. Med. Assoc. April 1997. Vol. 47, No. 4, pp. 108-109</p> <p>Nielsen et al., "Interferon-a-induced changes in surface antigens in a hairy-cell leukemia (JOK-1,...)" Eur. J. Haematol. 1992, Vol. 48, No. 3, pp. 146-151</p> <p>Shan et al., "Synergistic Effects of the Fenertinide..." Clin. Cancer Res., 2001, 7(8):2490-5 (Abstract only)</p>	

Examiner Signature

M. T. Davis

Date Considered

06/18/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.